Classification of current anticancer immunotherapies

被引：393

作者：

Galluzzi, Lorenzo ^{[1
,2
,3
,4
]}

Vacchelli, Erika ^{[1
,2
,3
]}

Bravo-San Pedro, Jose-Manuel ^{[1
,2
,3
]}

Buque, Aitziber ^{[1
,2
,3
]}

Senovilla, Laura ^{[1
,2
,3
]}

Baracco, Elisa Elena ^{[1
,2
,3
,5
]}

Bloy, Norma ^{[1
,2
,3
,5
]}

Castoldi, Francesca ^{[1
,2
,3
,5
,6
]}

Abastado, Jean-Pierre ^{[7
]}

Agostinis, Patrizia ^{[8
]}

Apte, Ron N. ^{[9
]}

Aranda, Fernando ^{[1
,2
,3
,10
]}

Ayyoub, Maha ^{[11
,12
]}

Beckhove, Philipp ^{[13
]}

Blay, Jean-Yves ^{[14
,15
]}

Bracci, Laura ^{[16
]}

Caignard, Anne ^{[17
,18
]}

Castelli, Chiara ^{[19
]}

Cavallo, Federica ^{[20
]}

Celis, Estaban ^{[21
]}

Cerundolo, Vincenzo ^{[22
]}

Clayton, Aled ^{[23
,24
]}

Colombo, Mario P. ^{[19
]}

Coussens, Lisa ^{[25
]}

Dhodapkar, Madhav V. ^{[26
]}

Eggermont, Alexander M. ^{[3
]}

Fearon, Douglas T. ^{[27
]}

Fridman, Wolf H. ^{[2
,4
,28
,29
]}

Fucikova, Jitka ^{[6
,30
,31
]}

Gabrilovich, Dmitry I. ^{[32
]}

Galon, Jerome ^{[2
,4
,28
,33
]}

Garg, Abhishek ^{[8
]}

Ghiringhelli, Francois ^{[34
,35
,36
]}

Giaccone, Giuseppe ^{[37
,38
]}

Gilboa, Eli ^{[39
]}

Gnjatic, Sacha ^{[40
]}

Hoos, Axel ^{[41
]}

Hosmalin, Anne ^{[4
,42
,43
,44
]}

Jaeger, Dirk ^{[45
]}

Kalinski, Pawel ^{[46
,47
,48
]}

Kaerre, Klas ^{[49
]}

Kepp, Oliver ^{[1
,2
,50
]}

Kiessling, Rolf ^{[51
]}

Kirkwood, John M. ^{[52
]}

Klein, Eva ^{[49
]}

Knuth, Alexander ^{[53
]}

Lewis, Claire E. ^{[54
]}

Liblau, Roland ^{[55
,56
,57
]}

Lotze, Michael T. ^{[46
,47
]}

Lugli, Enrico ^{[58
]}

机构：

[1] Ctr Rech Cordeliers, Equipe Labellisee Pas Ligue Natl Canc 11, Paris, France

[2] INSERM, U1138, Paris, France

[3] Gustave Roussy Canc Campus, Villejuif, France

[4] Univ Paris 05, Sorbonne Paris Cite, Paris, France

[5] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France

[6] Sotio Ac, Prague, Czech Republic

[7] Inst Rech Int Servier, Pole Innovat Therapeut Oncol, Suresnes, France

[8] Univ Leuven, Dept Cellular & Mol Med, Cell Death Res & Therapy CDRT Lab, Leuven, Belgium

[9] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol Immunol & Genet, Beer Sheva, Israel

[10] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Grp Immune Receptors Innate & Adapt Syst, Barcelona, Spain

[11] INSERM, U1102, St Herblain, France

[12] Inst Cancerol Ouest, St Herblain, France

[13] German Canc Res Ctr, Translat Immunol Div, Heidelberg, Germany

[14] CLR, Equipe 11, Lyon, France

[15] CRCL, Lyon, France

[16] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy

[17] INSERM, U1160, Paris, France

[18] Grp Hosp St Louis Lariboisiere F Vidal, Paris, France

[19] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Immunotherapy Human Tumors, Milan, Italy

[20] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Ctr Mol Biotechnol, Turin, Italy

[21] Georgia Regents Univ, Ctr Canc, Canc Immunol Inflammat & Tolerance Program, Augusta, GA USA

[22] Univ Oxford, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England

[23] Cardiff Univ, Sch Med, Inst Canc & Genet, Cardiff CF10 3AX, S Glam, Wales

[24] Velindre Canc Ctr, Cardiff, S Glam, Wales

[25] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[26] Yale Univ, Yale Canc Ctr, Sect Hematol & Immunobiol, New Haven, CT USA

[27] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA

[28] Univ Paris 06, Paris, France

[29] Ctr Rech Cordeliers, Equipe 13, Paris, France

[30] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic

[31] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic

[32] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA

[33] Ctr Rech Cordeliers, Lab Integrat Canc Immunol, Paris, France

[34] INSERM, UMR866, Dijon, France

[35] Ctr Georges Francois Leclerc, Dijon, France

[36] Univ Bourgogne, Dijon, France

[37] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[38] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[39] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Microbiol & Immunol, Miami, FL 33136 USA

[40] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Sect Hematol Oncol Immunol, New York, NY 10029 USA

[41] GlaxoSmithKline, Canc Immunotherapy Consortium, Collegeville, PA USA

[42] INSERM, U1016, Paris, France

[43] CNRS, UMR8104, Paris, France

[44] Hop Cochin, AP HP, F-75674 Paris, France

[45] Univ Med Ctr Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany

[46] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA

[47] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA USA

[48] Univ Pittsburgh, Dept Immunol & Infect Dis & Microbiol, Pittsburgh, PA USA

[49] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden

[50] Gustave Roussy Canc Campus, Metab & Cell Biol Platforms, Villejuif, France

来源：

ONCOTARGET | 2014年 / 5卷 / 24期

基金：

英国医学研究理事会; 欧洲研究理事会;

关键词：

adoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonists; HUMAN DENDRITIC CELLS; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; COLONY-STIMULATING FACTOR; ISOLATED LIMB PERFUSION; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES; LENALIDOMIDE PLUS DEXAMETHASONE; DEPENDENT CELLULAR CYTOTOXICITY;

D O I：

10.18632/oncotarget.2998

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.

引用

页码：12472 / 12508

页数：37

共 540 条

[1]

Uncovering the mechanisms that regulate tumor-induced T-cell anergy [J].

Abe, Brian T. ;

Macian, Fernando .

ONCOIMMUNOLOGY, 2013, 2 (02)

[2]

Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression [J].

Abrams, Scott I. ;

Waight, Jeremy D. .

ONCOIMMUNOLOGY, 2012, 1 (04)

[3]

Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation [J].

Adler, Adam J. ;

Vella, Anthony T. .

ONCOIMMUNOLOGY, 2013, 2 (01)

[4]

B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas [J].

Affara, Nesrine I. ;

Ruffell, Brian ;

Medler, Terry R. ;

Gunderson, Andrew J. ;

Johansson, Magnus ;

Bornstein, Sophia ;

Bergsland, Emily ;

Steinhoff, Martin ;

Li, Yijin ;

Gong, Qian ;

Ma, Yan ;

Wiesen, Jane F. ;

Wong, Melissa H. ;

Kulesz-Martin, Molly ;

Irving, Bryan ;

Coussens, Lisa M. .

CANCER CELL, 2014, 25 (06) :809-821

[5]

Personalizing immunotherapy Balancing predictability and precision [J].

Agur, Zvia ;

Vuk-Pavlovic, Stanimir .

ONCOIMMUNOLOGY, 2012, 1 (07) :1169-1171

[6]

IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients [J].

Ahmadzadeh, M ;

Rosenberg, ST .

BLOOD, 2006, 107 (06) :2409-2414

[7]

Links between Toll-like receptor 4 and breast cancer [J].

Ahmed, Abubakr ;

Redmond, H. Paul ;

Wang, Jiang Huai .

ONCOIMMUNOLOGY, 2013, 2 (02)

[8]

Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[9]

The tumour microenvironment as a target for chemoprevention [J].

Albini, Adriana ;

Sporn, Michael B. .

NATURE REVIEWS CANCER, 2007, 7 (02) :139-147

[10]

Cancer prevention by targeting angiogenesis [J].

Albini, Adriana ;

Tosetti, Francesca ;

Li, Vincent W. ;

Noonan, Douglas M. ;

Li, William W. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (09) :498-509

← 1 2 3 4 5 6 7 8 9 10 →